| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3273304 | Journal de Gynécologie Obstétrique et Biologie de la Reproduction | 2009 | 5 Pages |
Abstract
Tamoxifen is widely used in the breast cancer treatment. Its side effects on the endometrium are well-known, but more and more worse prognosis uterine sarcoma are described. Based on recent literature review, the cause and effect chain between tamoxifen and uterine sarcoma is argued, which confirms that a risk exists as from 2Â years of treatment, a cumulative dose of 15Â g, and that malignant mixed mesodermal tumours appear to be the most frequent.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
L. Homer, M. Muller, P.-F. Dupré, B. Lucas, O. Pradier,